Letter to the Editor
To the Editor:
In a recent article in the Journal of Cerebral Blood Flow and Metabolism, Lear and Ackermann (1988) compared brain auto radiographic images from rats injected with both [18F]-fluorode oxyglucose (FDG) and e4C]-glucose. A major con tribution of this work is that it takes a significant step in the process of defining when one tracer may be preferable to another.
The authors tentatively conclude that [6_14C]_ glucose may be the isotope of choice for experi ments in which the period of observation must be considerably less than the 45 min period used for FDG and deoxyglucose (DG). They express con cern, however, that in the brain areas with the high est rates of glucose utilization in the normal rat, the values found with FDG as tracer exceed those found with [6-14C]-glucose by up to 10%. If there is a 10% discrepancy under normal conditions, and if this is due to loss of products of [6_14C]-glucose metabolism, then might not the "underestimate" with [6-14C]_glucose as tracer become much greater under stimulated conditions? In fact, question the authors, is this not what Collins et aI. (1987) found in their studies of glucose metabolic rates in supe rior colliculi of rats exposed to progressively more rapid rates of visual flicker stimulation? It is to this issue of increased loss with increased activity that this letter addresses itself.
A methodological problem with the study of Lear and Ackermann (1988) is that the periods of obser vation were not the same for both tracers, i.e., in order to compare autoradiographs based on a 6-24 min experimental period after [6-14C]-glucose injec tion with autoradiographs based on a 45 min ex perimental period after FDG injection, the [6_14C]-glucose had to be administered 21-39 min after the FDG was injected. In the experiments of min later under a wide variety of conditions (Miller and Corddry, 1981; Miller et aI., 1982a Miller et aI., , 1982b Miller et aI., , 1984a Miller et aI., , 1984b Miller and Medina, 1986) . In these experiments, methods to rapidly inactivate brain enzymes were used and brain extracts were chro matographically separated into precursor and prod uct components. Thus, calculations of rates of glu cose utilization did not require knowledge of the rate constants of transport. The reason for using two different tracers was that conditions were being studied in which the underlying assumption that the metabolic products of each tracer are completely, or nearly completely, retained in the brain might be in error. The data have been consistent in showing that both tracers yielded similar results. Of special note is the observation that the large increases in CMRglc were similar during seizures produced by electroconvulsive shock (Miller et aI., 1982b) and by pentylenetetrazol (Miller et aI., 1984b) . In the work on pentylenetetrazol, in fact, there was a ten dency for the percent increases found with [6)4C]-glucose as tracer to exceed those found with FDG as tracer.
U sing an entirely different approach, Kloiber and Drewes (1987) examined loss of 14C02 and 14C me tabolites from dog brain perfused with blood con taining [6-14C]-glucose. Release of 14C02 over 10 min of perfusion rose to only 3% of e4C]-glucose taken up, and was similar even when rates were doubled by soman administration.
The above-cited studies were not designed as tests of the relative usefulness of glucose and DG or FDG as tracers. Nevertheless, they show that the results with each tracer are similar, even during pe riods of very rapid glucose use. Clearly, there will be more rapid loss of 14C02 when aerobic metabo lism of glucose is more rapid. Our studies, as well as PET studies of humans (Fox et aI., 1988) , however, indicate that the initial effect of brain activation is an increase in glycolytic rate with little change in oxygen consumption, resulting in lactate accumula tion. Thus, the expected increase in rate of 14C02 production is delayed. Moreover, the more rapid the rate of glycolysis, the shorter the period until the background of unmetabolized glucose (or DG or FDG) is acceptably low.
Thus, the available data on tracer uptake and re tention by brain shortly after coadministration of labeled glucose and DG are reassuring that it is pos-
